Michal Geva is Senior Vice President, Head of Research at Prilenia. Michal is responsible for developing and implementing research and scientific strategy, and managing scientific innovation and coherence across the company’s pipeline and strategy around corporate intellectual property (IP). Michal is also responsible for clinical data analyses and plays a key role in supporting early- and late-stage clinical development, regulatory strategy, and pre-commercialization activities.

Michal manages and maintains relationships with external key opinion leaders (KOLs) to support mechanism of action studies evaluation of new indications and potential new assets for expanding the corporate pipeline. She is responsible for developing strategy for drug development, including toxicology, pharmacology, DMPK, and clinical pharmacology. Michal brings extensive experience in pharmacology and drug development.

Prior to Prilenia, Michal was the Scientific and Non-Clinical Lead at Teva Pharmaceutical’s Global R&D. In that role, Michal supported the development of numerous CNS drugs across the clinical development stages, from discovery to Phase 3 and post-marketing life-cycle management. Michal led all scientific and non-clinical activities for pridopidine, Prilenia’s key asset in clinical development. Michal is a co-inventor of more than 10 patents/patent applications.

Michal did her post-doctoral fellowship at the Institute of Neurodegenerative Diseases, University of California, San Francisco (UCSF), under the mentorship of Nobel Laureate Stanley B. Prusiner and has a PhD from the Department of Cell Research & Immunology at Tel Aviv University.

• 

  SVP, Head of Research in Prilenia

  Pursuing Hope. Leading With Science.